Hypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
AstraZeneca PLC
AZN
Current price
$79.17
The company's successful Phase 3 trial for its novel hypertension drug, baxdrostat, is the primary catalyst for this theme. Its leadership in this spe...
The company's successful Phase 3 trial for its novel hypertension drug, baxdrostat, is the primary catalyst for this theme. Its leadership in this specific area makes it a core holding.
Eli Lilly and Company
LLY
Current price
$701.23
A major pharmaceutical company with a strong and growing pipeline in cardiovascular and metabolic diseases, including treatments that indirectly benef...
A major pharmaceutical company with a strong and growing pipeline in cardiovascular and metabolic diseases, including treatments that indirectly benefit hypertensive patients.
Novo Nordisk A/S
NVO
Current price
$52.41
A global leader in diabetes and obesity care, conditions that are heavily co-morbid with hypertension. Its research into metabolic diseases has signif...
A global leader in diabetes and obesity care, conditions that are heavily co-morbid with hypertension. Its research into metabolic diseases has significant overlap.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
AstraZeneca's successful baxdrostat trial has validated a new pathway for treating resistant hypertension. This breakthrough could reinvigorate the entire cardiovascular therapeutic landscape, potentially boosting valuations for companies developing novel treatments for hypertension and related conditions like kidney disease.
What You Need to Know
Hypertension affects over a billion people globally, with many struggling to control their blood pressure with existing medications. This represents a massive market opportunity for pharmaceutical companies that can develop effective new treatments with novel mechanisms of action.
Why These Stocks
These companies were selected for their leadership in cardiovascular, metabolic, and kidney disease research. From the headline-maker AstraZeneca to companies with complementary expertise in related conditions, each has potential to benefit from renewed interest in hypertension innovation.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+38.23%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 38.23% over the next year.
Stocks Rated Buy by Analysts
12 of 16 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Billion-Person Market Opportunity
With over a billion people worldwide suffering from hypertension and many struggling with current treatments, successful new therapies could achieve blockbuster status quickly.
Validated New Treatment Pathway
AstraZeneca's success with baxdrostat has validated a completely new approach to treating resistant hypertension, potentially triggering renewed investment across the entire field.
Breakthrough Moment for Heart Health
We're witnessing a potential turning point in cardiovascular medicine that could boost valuations for companies involved in this space, especially as clinical successes accumulate.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Uncle Sam's Semiconductor Stake
The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.
The Cybersecurity Consolidation Wave
Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.
American Chipmakers: A Tariff-Driven Shift
President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.
Frequently Asked Questions
Everything you need to know about the product and billing.